90434-01-8

Basic information

• Product Name: 3-iodo-N-methylbenzamide
• Synonyms: 3-iodo-N-methylbenzamide
• CAS NO: 90434-01-8
• Molecular Formula: C₈H₈INO
• Molecular Weight: 261.06
• Mol File: 90434-01-8.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C(protect from light)
• CAS DataBase Reference: 3-iodo-N-methylbenzamide(CAS DataBase Reference)
• NIST Chemistry Reference: 3-iodo-N-methylbenzamide(90434-01-8)
• EPA Substance Registry System: 3-iodo-N-methylbenzamide(90434-01-8)

Safety Data

• Hazardous Substances Data: 90434-01-8(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
3-Iodo-N-methylbenzamide is used as a building block in organic synthesis for the creation of various biologically active molecules. Its unique structure, featuring a methyl group and an iodine atom attached to the benzene ring, allows for the development of a wide range of compounds with potential applications in different fields.
Used in Pharmaceutical Research:
In pharmaceutical research, 3-Iodo-N-methylbenzamide is utilized as a key component in the synthesis of new drugs and drug candidates. Its structural similarity to other biologically active compounds makes it a valuable asset in the discovery and development of novel therapeutic agents.
Used in Medicinal Chemistry:
3-Iodo-N-methylbenzamide may have potential applications in medicinal chemistry, where it can be used to explore the structure-activity relationships of various compounds. This can lead to the optimization of drug candidates and the development of more effective treatments for a variety of diseases and conditions.
Used in Drug Development:
Due to its potential as a building block for the synthesis of biologically active molecules, 3-Iodo-N-methylbenzamide can be employed in drug development to create new pharmaceuticals. Its unique properties and structural features make it a promising candidate for the development of innovative treatments and therapies.

Upstream product

• 618-91-7 methyl 3-iodo-benzoate 
• 593-51-1 methylamine hydrochloride 
• 618-51-9 3-Iodobenzoic acid 
• 1197171-76-8 N-methyl-3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzamide 
• 1711-10-0 3-iodobenzoyl chloride 
• 74-89-5 methylamine 

Downstream Products

• 1033438-99-1 N-methyl-3-[(trimethylsilyl)ethynyl]benzamide 
• 694528-54-6 trans-iodo(N-methylbenzamide-C⁽³⁾)bis(triphenylphosphine)platinum(II) 

Relevant articles and documents

Optimization of 4,6-Disubstituted Pyrido[3,2-d]pyrimidines as Dual MNK/PIM Inhibitors to Inhibit Leukemia Cell Growth

Mitogen-activated protein kinase-interacting kinases (MNKs) and provirus integration in maloney murine leukemia virus kinases (PIMs) are downstream enzymes of cell proliferation signaling pathways associated with the resistance of tyrosine kinase inhibitors. MNKs and PIMs have complementary effects to regulate cap-dependent translation of oncoproteins. Dual inhibitors of MNKs and PIMs have not been developed. We developed a novel 4,6-disubstituted pyrido[3,2-d]pyrimidine compound 21o with selective inhibition of MNKs and PIMs. The IC50’s of 21o to inhibit MNK1 and MNK2 are 1 and 7 nM and those to inhibit PIM1, PIM2, and PIM3 are 43, 232, and 774 nM, respectively. 21o inhibits the growth of myeloid leukemia K562 and MOLM-13 cells with GI50’s of 2.1 and 1.2 μM, respectively. 21o decreases the levels ofp-eIF4E andp-4EBP1, the downstream products of MNKs and PIMs, as well as cap-dependent proteins c-myc, cyclin D1, and Mcl-1. 21o inhibits the growth of MOLM-13 cell xenografts without causing evident toxicity. 21o represents an innovative dual MNK/PIM inhibitor with a good pharmacokinetic profile.

CARDIAC SARCOMERE INHIBITORS

Provided are compounds of Formula (I), or a pharmaceutically acceptable salt thereof, wherein R1, R2A, R2B, R3, R4, and R5 are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

4, 6-disubstituted pyridine [3, 2-d] pyrimidine compound as well as preparation and application thereof

The invention belongs to the technical field of medicines. The invention relates to the field of pharmaceutical chemistry, in particular to a 4, 6-disubstituted pyridine [3, 2-d] pyrimidine compound and pharmaceutically acceptable salt thereof, a preparation method of the compound, a pharmaceutical composition taking the compound as an active ingredient, and application of the compound in preparation of an MNK inhibitor and drugs for treating and/or preventing various cancers and/or metabolic diseases. The present invention relates to compounds represented by formulas I, II, III or IV, and pharmaceutically acceptable salts, hydrates, solvates and metabolites thereof, wherein the variables are described in the claims and the description.

Iridium-catalyzed, ligand-controlled directed alkynylation and alkenylation of arenes with terminal alkynes

We report iridium-catalyzed C-C formation between benzamides and terminal alkynes. With the choice of a suitable ligand, a C-H alkynylation or alkenylation product could be obtained selectively. The directed C-H alkynylation proceeded without the need for an external oxidant, while the directed C-H alkenylation likely involves an unusual vinylidene mechanism. This divergent reactivity provides access to both alkynylation and alkenylation products from the same set of starting materials.

Chemoselective Synthesis of Aryl Ketones from Amides and Grignard Reagents via C(O)-N Bond Cleavage under Catalyst-Free Conditions

Conversion of a wide range of N-Boc amides to aryl ketones was achieved with Grignard reagents via chemoselective C(O)-N bond cleavage. The reactions proceeded under catalyst-free conditions with different aryl, alkyl, and alkynyl Grignard reagents. α-Ketoamide was successfully converted to aryl diketones, while α,β-unsaturated amide underwent 1,4-addition followed by C(O)-N bond cleavage to provide diaryl propiophenones. N-Boc amides displayed higher reactivity than Weinreb amides with Grignard reagents. A broad substrate scope, excellent yields, and quick conversion are important features of this methodology.

Sterically controlled iodination of arenes via iridium-catalyzed C-H borylation

A mild method to prepare aryl and heteroaryl iodides by sequential C-H borylation and iodination is reported. The regioselectivity of this process is controlled by steric effects on the C-H borylation step and is complementary to existing methods to form aryl iodides. The iodination of boronic esters has potential for the synthesis of radiolabeled aryl iodides, as demonstrated by the concise synthesis of a potential tracer for SPECT imaging.

ALKYNYLPYRIMIDINES AS TIE2 KINASE INHIBITORS

The invention relates to alkynylpyrimidines according to the general formula (I) in which A, R1, R2, R3, R4, R5, and R6 are as defined in the claims, to pharmaceutical compositions comprising said alkynylpyrimidines, to methods of preparing said alkynylpyrimidines, as well as to uses thereof for manufacturing a pharmaceutical composition for the treatment of diseases of dysregulated vascular growth or of diseases which are accompanied with dysregulated vascular growth, wherein the compounds effectively interfere with Tie2 and VEGFR2 signalling.

Synthesis and redistribution reactions of asymmetric σ-arylplatinum(II) complexes containing 4,7-phenanthroline

The mononuclear σ-aryl complexes of the type trans -[Pt(σ -C6H4R)(4,7-phen)(PPh3)2] OTf (R=4-CO2SitBuPh2, 4-CONHMe, 3-CO2SitBuPh2, 3-CONHMe; OTf=trifluoromethanesulfonate) containing a monodentate 4,7-phenanthroline (4,7-phen) ligand were prepared by an oxidative addition reaction of an aryl iodide with Pt(PPh3) 4 to yield the key iodoplatinum(II) precursors trans -[PtI(σ-C6H4R)(PPh3) 2], followed by halogen metathesis with one equivalent of 4,7-phen. The reaction of trans -[Pt(σ-C6 H4R)(4,7-phen)(PPh3)2]OTf with labile complexes of the type trans -[Pt(OTf)L2(σ -C6H4R′)] (L=PEt3, R′=H; L=PPh3, R′=4-CO2SitBuPh2 3-CO2SitBuPh2, 3-CONHMe) afforded the asymmetric dinuclear complexes of the type trans -[Pt(σ -C6H4R)L2(μ-4,7-phen)Pt(σ -C6H4R′) L′2](OTf) 2 (L=PPh3, R=4-CO2SitBuPh2, L′=PEt3, R′=H; L=L′=PPh3, R=4-CONHMe, R′ =4-CO2SitBuPh2; R=4-CO2SitBuPh2, R′=3-CONHMe; R=3-CONHMe, R′=3 -CO2SitBuPh2) in which the 4,7-phen acts as a bridging bidentate ligand. The novel dinuclear species undergo an unusual redistribution reaction that is essentially thermoneutral at 298 K. The exchange process involves facile cleavage of a Pt-N bond and the rapid exchange of trans -[PtL2(σ-aryl)] units in the equilibrium mixture.